510 related articles for article (PubMed ID: 21704583)
1. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin.
Kirkpatrick GJ; Plumb JA; Sutcliffe OB; Flint DJ; Wheate NJ
J Inorg Biochem; 2011 Sep; 105(9):1115-22. PubMed ID: 21704583
[TBL] [Abstract][Full Text] [Related]
2. Dendrimer-platinate: a novel approach to cancer chemotherapy.
Malik N; Evagorou EG; Duncan R
Anticancer Drugs; 1999 Sep; 10(8):767-76. PubMed ID: 10573209
[TBL] [Abstract][Full Text] [Related]
3. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
4. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality.
Majoros IJ; Myc A; Thomas T; Mehta CB; Baker JR
Biomacromolecules; 2006 Feb; 7(2):572-9. PubMed ID: 16471932
[TBL] [Abstract][Full Text] [Related]
5. Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs.
Pisani MJ; Wheate NJ; Keene FR; Aldrich-Wright JR; Collins JG
J Inorg Biochem; 2009 Mar; 103(3):373-80. PubMed ID: 19121543
[TBL] [Abstract][Full Text] [Related]
6. Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation.
Kulhari H; Pooja D; Singh MK; Chauhan AS
Drug Dev Ind Pharm; 2015 Feb; 41(2):232-8. PubMed ID: 24237325
[TBL] [Abstract][Full Text] [Related]
7. In vitro gene delivery using polyamidoamine dendrimers with a trimesyl core.
Zhang XQ; Wang XL; Huang SW; Zhuo RX; Liu ZL; Mao HQ; Leong KW
Biomacromolecules; 2005; 6(1):341-50. PubMed ID: 15638538
[TBL] [Abstract][Full Text] [Related]
8. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo.
Liu C; Liu X; Rocchi P; Qu F; Iovanna JL; Peng L
Bioconjug Chem; 2014 Mar; 25(3):521-32. PubMed ID: 24494983
[TBL] [Abstract][Full Text] [Related]
9. Three new asymmetric trans-amine(azole)dichloridoplatinum complexes that overcome cisplatin resistance and their reactions with 5'-GMP.
Pantoja E; Gallipoli A; van Zutphen S; Komeda S; Reddy D; Jaganyi D; Lutz M; Tooke DM; Spek AL; Navarro-Ranninger C; Reedijk J
J Inorg Biochem; 2006 Dec; 100(12):1955-64. PubMed ID: 17083978
[TBL] [Abstract][Full Text] [Related]
10. para-Sulfonatocalix[4]arene and polyamidoamine dendrimer nanocomplexes as delivery vehicles for a novel platinum anticancer agent.
Pang CT; Ammit AJ; Ong YQE; Wheate NJ
J Inorg Biochem; 2017 Nov; 176():1-7. PubMed ID: 28810174
[TBL] [Abstract][Full Text] [Related]
11. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
12. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
[TBL] [Abstract][Full Text] [Related]
13. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate.
Li X; Li R; Qian X; Ding Y; Tu Y; Guo R; Hu Y; Jiang X; Guo W; Liu B
Eur J Pharm Biopharm; 2008 Nov; 70(3):726-34. PubMed ID: 18634874
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice.
Moreno D; Zalba S; Navarro I; Tros de Ilarduya C; Garrido MJ
Eur J Pharm Biopharm; 2010 Feb; 74(2):265-74. PubMed ID: 19883755
[TBL] [Abstract][Full Text] [Related]
15. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex.
Patri AK; Kukowska-Latallo JF; Baker JR
Adv Drug Deliv Rev; 2005 Dec; 57(15):2203-14. PubMed ID: 16290254
[TBL] [Abstract][Full Text] [Related]
16. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
17. Encapsulation of 2-methoxyestradiol within multifunctional poly(amidoamine) dendrimers for targeted cancer therapy.
Wang Y; Guo R; Cao X; Shen M; Shi X
Biomaterials; 2011 Apr; 32(12):3322-9. PubMed ID: 21315444
[TBL] [Abstract][Full Text] [Related]
18. New isomeric azine-bridged dinuclear platinum(II) complexes circumvent cross-resistance to cisplatin.
Komeda S; Kalayda GV; Lutz M; Spek AL; Yamanaka Y; Sato T; Chikuma M; Reedijk J
J Med Chem; 2003 Mar; 46(7):1210-9. PubMed ID: 12646031
[TBL] [Abstract][Full Text] [Related]
19. Tumor targeting using polyamidoamine dendrimer-cisplatin nanoparticles functionalized with diglycolamic acid and herceptin.
Kesavan A; Ilaiyaraja P; Sofi Beaula W; Veena Kumari V; Sugin Lal J; Arunkumar C; Anjana G; Srinivas S; Ramesh A; Rayala SK; Ponraju D; Venkatraman G
Eur J Pharm Biopharm; 2015 Oct; 96():255-63. PubMed ID: 26277659
[TBL] [Abstract][Full Text] [Related]
20. Carboxymethyl chitosan-poly(amidoamine) dendrimer core-shell nanoparticles for intracellular lysozyme delivery.
Zhang X; Zhao J; Wen Y; Zhu C; Yang J; Yao F
Carbohydr Polym; 2013 Nov; 98(2):1326-34. PubMed ID: 24053810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]